Detection of Different Virus-Specific CD8+ T Cells after Kidney Transplantation

Mees, Soeren Torge; Kebschull, Linus; Mardin, Wolf Arif; Senninger, N.; Suwelack, Barbara; Haier, Joerg

doi:10.1089/sur.2013.083

Cited by 3 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The commercially developed iTAg TM [Ni 2+ -nitrilotriacetic acid (NTA)–His-tag Chelate complexes] class I MHC Tetramers (Beckman Coulter, Krefeld, Germany) allow the staining of epitope-specific CD8 + T lymphocytes [ 85 ]. Mees et al evaluated the CMV-specific CD8 + T lymphocytes in 23 kidney transplant recipients using the CMV-specific iTAg TM class I pMHC Tetramers (Beckman Coulter, Germany) with the CMV-Ag specific pMHC-tetramers restricted by five different HLA-A and HLA-B alleles for 6 months after SOT [ 86 ]. The CMV-specific tetramers did not play a significant role in predicting CMV replication after SOT, because of small number of CMV viremia or disease [ 86 ].…”

Section: Cmv-cmimentioning

confidence: 99%

“…Mees et al evaluated the CMV-specific CD8 + T lymphocytes in 23 kidney transplant recipients using the CMV-specific iTAg TM class I pMHC Tetramers (Beckman Coulter, Germany) with the CMV-Ag specific pMHC-tetramers restricted by five different HLA-A and HLA-B alleles for 6 months after SOT [ 86 ]. The CMV-specific tetramers did not play a significant role in predicting CMV replication after SOT, because of small number of CMV viremia or disease [ 86 ]. A study by Brooimans et al suggested that the standardized single-platform iTAg TM class I CMV-specific pMHC Tetramer assays against the TCRs specific for the three different MHC class I CMV peptides were reproducible and useful for enumerating the CMV-specific T lymphocytes [ 87 ].…”

Section: Cmv-cmimentioning

confidence: 99%

See 1 more Smart Citation

Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies

Han

2017

Infect Chemother

View full text Add to dashboard Cite

The current cytomegalovirus (CMV) prevention strategies in solid organ transplantation (SOT) recipients have contributed towards overcoming the detrimental effects caused by CMV lytic infection, and improving the long-term success rate of graft survival. Although the quantification of CMV in peripheral blood is the standard method, and an excellent end-point for diagnosing CMV replication and modulating the anti-CMV prevention strategies in SOT recipients, a novel biomarker mimicking the CMV control mechanism is required. CMV-specific immune monitoring can be employed as a basic tool predicting CMV infection or disease after SOT, since uncontrolled CMV replication mostly originates from the impairment of immune responses against CMV under immunosuppressive conditions in SOT recipients. Several studies conducted during the past few decades have indicated the possibility of measuring the CMV-specific cell-mediated immune response in clinical situations. Among several analytical assays, the most advancing standardized tool is the QuantiFERON®-CMV assay. The T-Track® CMV kit that uses the standardized enzyme-linked immunospot assay is also widely employed. In addition to these assays, immunophenotyping and intracellular cytokine analysis using flow cytometry (with fluorescence-labeled monoclonal antibodies or peptide-major histocompatibility complex multimers) needs to be adequately standardized and validated for potential clinical applications.

show abstract

Section: Cmv-cmimentioning

confidence: 99%

Section: Cmv-cmimentioning

confidence: 99%

Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies

Han

2017

Infect Chemother

View full text Add to dashboard Cite

show abstract

“…Its combination with EBV-specific T-cell responses could allow a more precise assessment of patients at risk as well as of treatment efficacy. EBVspecific T-cell responses can be quantified by ELISPOT [101][102][103][104], ICS [105,106] and pMHC multimer staining [101,107] or by combining pMHC multimer staining and ICS techniques [106] in SOT recipients. A recent study compared five immunoassays [the functional EBV-specific IFN-␥ ELISPOT, ICS, ELISA and cytokine secretion assays (CSA) and the detection of EBV-specific T cells by pMHC multimer staining] in healthy subjects and identified the peptidebased IFN-␥ ELISPOT as the most accurate technique for immune monitoring and CSA for a more detailed phenotypic and functional analysis of T cells [74].…”

Section: Ebvmentioning

confidence: 99%

Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications

Calarota

Aberle

Puchhammer‐Stöckl

et al. 2015

Journal of Clinical Virology

View full text Add to dashboard Cite

Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8+ T cells

et al. 2018

View full text Add to dashboard Cite

Human Cytomegalovirus (CMV) reactivation remains a major source of morbidity in patients after solid organ and hematopoietic stem cell transplantation (HSCT). Adoptive T cell therapy (ACT) with CMV-specific T cells is a promising therapeutic approach for HSCT recipients, but might be counteracted by CMV’s immune evasion strategies. HLA-C*07:02 is less susceptible to viral immune evasion suggesting HLA-C*07:02-restricted viral epitopes as promising targets for ACT. For a better understanding of HLA-C*07:02-restricted CMV-specific T cells we used recently generated reversible HLA-C*07:02/IE-1 multimers (Streptamers) recognizing a CMV-derived Immediate-Early-1 (IE-1) epitope and analyzed phenotypic and functional T cell characteristics. Initially, we detected very high frequencies of HLA-C*07:02/IE-1 multimer+ T cells (median = 11.35%), as well as robust functional responses after stimulation with IE-1 peptide (IFNγ+; median = 5.02%) in healthy individuals. However, MHC-multimer+ and IFNγ-secreting T cell frequencies showed a relatively weak correlation (r2 = 0.77), which could be attributed to an unexpected contribution of CMV-epitope-independent KIR2DL2/3-binding of HLA-C*07:02/IE-1 multimers. Therefore, we developed a MHC-multimer double-staining approach against a cancer epitope-specific HLA-C*07:02 multimer to identify truly HLA-C*07:02/IE-1 epitope-specific T cells. The frequencies of these truly HLA-C*07:02/IE-1 multimer+ T cells were still high (median = 6.86%) and correlated now strongly (r2 = 0.96) with IFNγ-secretion. Interestingly, HLA-C*07:02/IE-1-restricted T cells contain substantial numbers with a central memory T cell phenotype, indicating high expansion potential e.g. for ACT. In line with that, we developed a clinical enrichment protocol avoiding epitope-independent KIR-binding to make HLA-C*07:02/IE-1-restricted T cells available for ACT. Initial depletion of KIR-expressing CD8+ T cells followed by HLA-C*07:02/IE-1 Streptamer positive selection using paramagnetic labeling techniques allowed to enrich successfully HLA-C*07:02/IE-1-restricted T cells. Such specifically enriched populations of functional HLA-C*07:02/IE-1-restricted T cells with significant central memory T cell content could become a potent source for ACT.

show abstract

Detection of Different Virus-Specific CD8+ T Cells after Kidney Transplantation

Cited by 3 publications

References 42 publications

Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies

Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies

Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications

Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8+ T cells

Contact Info

Product

Resources

About